Having trouble accessing articles? Reset your cache.

Aclidinium bromide and formoterol: Phase III data

Almirall and partner Forest reported top-line data from the 5-arm, double-blind, international Phase III ACLIFORM/COPD trial in 1,729 patients with moderate to severe COPD showing that both fixed-dose combinations of aclidinium bromide and formoterol delivered via Almirall's Genuair inhaler met the co-primary endpoints of improving

Read the full 450 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE